FAK inhibition has been shown to modulate the immune milieu and fibrosis within the TME and is accordingly being pursued in clinical studies as a potential therapeutic target along with standard chemotherapy and/or immunotherapy particularly in pancreatic cancer. The gene discussed is PTK2; the disease is pancreatic neoplasm.